<< Independent brain networks control human walking | Osteoporosis screening and treatment may be cost-effective for selected older men >>

Oncolytics Biotech issued new U.S. patent

Published on August 8, 2007 at 11:49 AM · No Comments

Oncolytics Biotech Inc. has announced that it has been granted U.S. Patent 7,252,817 entitled "Viruses for the Treatment of Cellular Proliferative Disorders."

The claims cover the use of modified herpes simplex viruses (HSV) to treat cellular proliferative disorders which include neoplasias (cancers). "This patent expands our intellectual property portfolio in viruses other than reovirus," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics.

http://www.oncolyticsbiotech.com/

4c19cd27-afc3-4887-af4e-1afb456a9f25|0|.0

Posted in: Medical Patent News

Tags: Herpes, Herpes Simplex

Peregrine Pharmaceuticals awarded U.S. patent for anti-viral applications of phospholipid-targeting antibodiesPeregrine Pharmaceuticals, Inc. has announced that the U.S. Patent and Trademark Office has issued U...
Increasing evidence a virus may play a role in breast cancerA new study finds increasing evidence a virus may play a role in breast cancer. The study finds near...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.